OM insider sale filing: 383 shares via Morgan Stanley; RSU settlement disclosed

Rhea-AI Filing Summary

Outset Medical, Inc. (OM) reported a proposed sale under Rule 144 of 383 shares of Common Stock through Morgan Stanley Smith Barney, with an aggregate market value of $4,933.04, targeted for sale on 08/15/2025 on NASDAQ. The filing shows the securities were acquired as settlement of vested restricted stock units on 08/15/2025 (748 shares) as equity compensation. The filer also reports a prior sale of 396 shares on 05/15/2025 that generated $7,057.86. The notice includes the customary representation that the seller is not aware of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Small-volume insider disposal tied to equity compensation; negligible dilution or market impact given outstanding shares.

The proposed transaction involves 383 shares versus 17,766,193 shares outstanding, representing an immaterial fraction of the equity base. The acquisition source—settlement of vested restricted stock units—indicates the sale is a monetization of compensation rather than a strategic disposal. The filing discloses a recent, modest sale of 396 shares producing $7,057.86, suggesting routine liquidity activity by an insider. For investors, this filing provides transparency on insider sales but does not, by itself, imply material change to company capitalization or control.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 requirements; no governance red flags apparent from the reported volumes and acquisition source.

The notice documents compliance with resale rules for restricted stock unit settlements and includes the standard representation regarding material nonpublic information. The involvement of a major broker and explicit description of the nature of acquisition (equity compensation) are appropriate governance practices. Given the small sizes relative to total shares outstanding, the filing does not indicate unusual insider behavior or immediate governance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 38th Floor New York NY 10004	383	4933.04	17766193	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/15/2025	Settlement of Vested Restricted Stock Units	Issuer			748	08/15/2025	Equity compensation for services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
John Brottem 3052 Orchard Drive San Jose CA 95134	Common Stock	05/15/2025	396	7057.86

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Outset Medical's Form 144 disclose about the proposed sale?

The Form 144 proposes to sell 383 shares of Common Stock through Morgan Stanley Smith Barney with an aggregate market value of $4,933.04, approx sale date 08/15/2025 on NASDAQ.

How were the shares being sold acquired according to the filing?

The filing shows 748 shares were acquired on 08/15/2025 as the settlement of vested restricted stock units, described as equity compensation for services rendered.

Has the seller sold any Outset Medical shares recently?

Yes; the filing reports a prior sale of 396 shares on 05/15/2025 that generated $7,057.86 in gross proceeds.

How large is the proposed sale relative to shares outstanding?

The proposed sale of 383 shares is small versus the reported 17,766,193 shares outstanding, indicating an immaterial percentage of the company's outstanding equity.

Does the filing indicate undisclosed material information about the company?

The signer represents they do not know any material adverse information regarding the issuer that has not been publicly disclosed.